Global stem cell therapy market is estimated to be valued at USD 15.15 Bn in 2024 and is expected to reach USD 63.23 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 22.6% from 2024 to 2031.
Report Coverage |
Report Details |
Base Year: |
2023 |
Market Size in 2024: |
US$ 15.15 Bn |
Historical Data for: |
2019 to 2023 |
Forecast Period: |
2024 to 2031 |
Forecast Period 2024 to 2031 CAGR: |
22.60% |
2031 Value Projection: |
US$ 63.23 Bn |
Figure. Stem Cell Therapy Market Share (%), By Region, 2024
![Stem Cell Therapy Market - IMG1](/sample/img/COH1490060-f1.webp)
Stem cell therapy is a promising and emerging field in regenerative medicine that involves the use of stem cells and their derivatives to repair or regenerate damaged tissues and cells. Stem cells are found in all human beings from a very early stage of life. These have the unique ability to renew themselves through cell division and differentiate into a diverse range of specialized cell types. These cells hold great potential to treat many incurable diseases through transplantation or tissue regeneration. Stem cell research aims to harness the natural powers of stem cells to develop therapies that can cure various diseases like cancer, diabetes, heart disease, osteoarthritis and neurological disorders.
Market Dynamics:
Global stem cell therapy market growth is driven by factors such as rising prevalence of chronic diseases, increasing success rates of stem cell therapies, rapid advancements in regenerative medicine, growing investments for research and development in stem cell therapies and approval of new therapies. However, high costs involved in stem cell research & development and therapeutic applications along with ethical issues related to embryonic stem cells can hamper the market growth. Emergence of new stem cell sources, development of advanced technology platforms for efficient production of stem cells, and application of artificial intelligence for faster development of customized stem cell therapies can offer opportunities for the market growth in the future. Providing affordable stem cell therapies globally and developing efficient techniques for stem cell banking can help to address unmet needs and expand the market reach.
Key Features of the Study:
- This report provides an in-depth analysis of the global stem cell therapy market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global stem cell therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this includes Osiris Therapeutics, Inc., Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., Anterogen Co. Ltd., Pharmicell Co., Inc., Stemedica Cell Technologies, Inc., Magellan, Medipost Co., Ltd, Athersys Inc., Biorestorative Therapies Inc., Brainstorm Cell Limited., ViaCyte Inc., Cellular Biomedicine Group, ANTEROGEN. C.O., LTD., NuVasive Inc., RTI Surgical, AlloSource.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- Global stem cell therapy market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global stem cell therapy market.
Detailed Segmentation-
- By Cell Source:
- Adult Stem Cells
- Induced Pluripotent Stem Cells
- Embryonic Stem Cells
- Others
- By Application:
- Musculoskeletal Disorders
- Wounds and Injuries
- Cancer
- Autoimmune Disorders
- Others
- By End User:
- Hospitals
- Cell Banks
- Academic and Research Institutes
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Osiris Therapeutics, Inc.
- Kolon TissueGene, Inc.
- JCR Pharmaceuticals Co., Ltd.
- Anterogen Co. Ltd.
- Pharmicell Co., Inc.
- Stemedica Cell Technologies, Inc.
- Magellan
- Medipost Co., Ltd
- Athersys Inc.
- Biorestorative Therapies Inc.
- Brainstorm Cell Limited.
- ViaCyte Inc.
- Cellular Biomedicine Group
- C.O., LTD.
- NuVasive Inc.
- RTI Surgical
- AlloSource